Daily Cardiology Research Analysis
Analyzed 222 papers and selected 3 impactful papers.
Summary
A first-line randomized trial shows pulsed field ablation (PFA) significantly outperforms antiarrhythmic drugs for persistent atrial fibrillation over 12 months, with acceptable safety. An individual-participant-data meta-analysis across randomized trials demonstrates that blood-pressure lowering confers consistent cardiovascular benefit across all stages of chronic kidney disease. A mechanistic study introduces a super-resolution electrochemistry method to map sympathetic norepinephrine dynamics in failing hearts and implicates Cav2.2 channels as a key driver.
Research Themes
- First-line catheter ablation for persistent atrial fibrillation
- Blood pressure lowering benefits across chronic kidney disease stages
- Sympathetic neurotransmission dynamics in heart failure
Selected Articles
1. Pulsed Field Ablation as Initial Therapy for Persistent Atrial Fibrillation.
In untreated persistent AF, first-line pulsed field ablation achieved higher 12-month treatment success than antiarrhythmic drugs (HR 0.46), with 5.1% device/procedure-related serious adverse events. Continuous monitoring ensured robust arrhythmia detection.
Impact: This is the first randomized trial to test PFA as initial therapy for persistent AF, showing superior efficacy over standard drug therapy with acceptable safety, potentially shifting first-line management.
Clinical Implications: PFA can be considered a first-line strategy in eligible patients with persistent AF, especially when rapid rhythm control and avoidance of long-term antiarrhythmic drug exposure are desired. Programs should prepare for adoption, operator training, and safety monitoring.
Key Findings
- PFA improved 12-month treatment success vs antiarrhythmic drugs (Kaplan–Meier 56% vs 30%; HR for failure 0.46, P<0.001).
- Device/procedure-related serious adverse events with PFA occurred in 5.1% of patients.
- Continuous insertable cardiac monitoring enabled rigorous detection of arrhythmia recurrence and burden.
Methodological Strengths
- International randomized design with continuous insertable cardiac monitoring
- Prespecified composite success endpoints capturing both procedural and long-term efficacy
Limitations
- Open-label design and lack of sham control may introduce performance bias
- 12-month follow-up limits assessment of very long-term durability and rare adverse events
Future Directions: Head-to-head trials of PFA versus thermal ablation, longer-term durability studies, and cost-effectiveness and quality-of-life analyses will clarify optimal positioning in care pathways.
BACKGROUND: Guidelines recommend a trial of antiarrhythmic drugs before catheter ablation for persistent atrial fibrillation. Whether pulsed field ablation (PFA) may be a preferred initial treatment is unclear. METHODS: We conducted an international, randomized trial involving patients with previously untreated persistent atrial fibrillation. The patients were randomly assigned in a 2:1 ratio to receive PFA performed with a pentaspline catheter or to receive antiarrhythmic-drug therapy. An additional group of patients (PFA-assigned) underwent PFA for the analysis of the primary safety end point alone. All the patients received an insertable cardiac monitor. The primary effectiveness end point was the short-term and long-term success of treatment through 12 months. Short-term success was defined as procedural success in the PFA group and the absence of ablation during the blanking period (90 days after treatment initiation) in the antiarrhythmic-drug group. Long-term success was defined as freedom from recurrence of atrial arrhythmias, repeat ablation, or need for antiarrhythmic drugs from 90 days through 12 months (in the PFA group) and freedom from amiodarone use at any time. The primary safety end point was device- and procedure-related serious adverse events. RESULTS: At 12 months, treatment success was observed in 128 of 207 patients (Kaplan-Meier estimate, 56%; 95% confidence interval [CI], 48 to 63) in the PFA group and in 40 of 103 patients (Kaplan-Meier estimate, 30%; 95% CI, 21 to 40) in the antiarrhythmic-drug group (hazard ratio for composite treatment failure [a lack of short- and long-term success], 0.46; 95% CI, 0.33 to 0.65; P<0.001). A primary safety end-point event occurred in 13 of 257 patients (5.1%) in the combined PFA group (both randomized and PFA-assigned groups). At 12 months, serious adverse events had occurred in 45 patients (25%) in the PFA group and in 20 patients (21%) in the antiarrhythmic-drug group. CONCLUSIONS: Among patients with persistent atrial fibrillation, the risk of recurrence of atrial arrhythmia was significantly lower among those who received PFA as first-line treatment than among those who received antiarrhythmic-drug therapy. (Funded by Boston Scientific; AVANT GUARD ClinicalTrials.gov number, NCT06096337.).
2. Pharmacological blood-pressure lowering for the prevention of cardiovascular disease and death across the full spectrum of chronic kidney disease severity: an individual-participant data meta-analysis.
Across 46 RCTs with 285,124 participants, a 5 mmHg reduction in systolic blood pressure reduced major cardiovascular events similarly in CKD and non-CKD, with consistent benefits across CKD stages and proteinuria status. Benefits were attenuated in CKD with diabetes, and drug-class effects paralleled those in the general population.
Impact: This IPD meta-analysis fills a critical evidence gap by quantifying cardiovascular benefit from BP lowering across the full CKD spectrum, informing guideline recommendations and individualized targets.
Clinical Implications: Treat-to-target blood-pressure strategies should be pursued in CKD patients, recognizing consistent cardiovascular risk reduction across stages; special consideration is warranted in CKD with diabetes where relative benefit is attenuated.
Key Findings
- A 5 mmHg systolic BP reduction lowered major cardiovascular events similarly in CKD (HR ~0.91) and non-CKD (HR ~0.90).
- Benefits were consistent across CKD stages 1–5, BP thresholds, and proteinuria status.
- Relative benefit was attenuated in CKD patients with concomitant diabetes, suggesting tailored strategies.
Methodological Strengths
- One-stage IPD meta-analysis across large RCT dataset with time-to-event outcomes
- Stratified analyses across CKD stages, diabetes, proteinuria, and antihypertensive classes
Limitations
- Exclusion of heart failure trials and extreme creatinine may limit generalizability to some high-risk subgroups
- Heterogeneity in trial designs and therapies over time requires cautious interpretation
Future Directions: Define optimal absolute BP targets across CKD phenotypes, evaluate intensified strategies in CKD with diabetes, and integrate kidney endpoints alongside cardiovascular outcomes.
BACKGROUND: Individuals with chronic kidney disease (CKD), particularly those at more advanced stages, have been systematically under-represented in randomised controlled trials (RCTs) of blood-pressure-lowering treatment due to safety concerns, leading to a persistent paucity of evidence for cardiovascular risk management in this high-risk group. We investigated the effect of blood-pressure-lowering treatment on the risk of major cardiovascular disease and death across the full spectrum of CKD stages and by key clinical subgroups. METHODS: We conducted a one-stage meta-analysis of individual-participant data from RCTs in which participants were randomly assigned to a blood-pressure-lowering therapy versus a comparator. We used RCTs collated in the Blood Pressure Lowering Treatment Trialists' Collaboration dataset, published at any time in any language, which were eligible for inclusion if they had at least 1000 person-years of follow-up per arm, baseline blood-pressure and creatinine measurements, and time-to-event outcomes; those with unclear randomisation procedures or restricted to heart failure or acute care settings were excluded. Participants with a documented history of heart failure or extreme creatinine values were excluded. No age criteria were applied. The primary outcome was major cardiovascular events, defined as a composite of fatal or non-fatal stroke, ischaemic heart disease, or hospitalisation for, or death from, heart failure. Relative treatment effects were estimated with a stratified Cox proportional hazards model. Heterogeneity of treatment effects was evaluated across prespecified subgroups defined by CKD status, CKD stage (1-5), diabetes, proteinuria, and baseline blood pressure. A stratified network meta-analysis was performed to examine whether treatment effects differed by defined subgroups within each of five principal antihypertensive drug classes. The systematic review was registered in PROSPERO (CRD42018099283). FINDINGS: From 52 RCTs (363 684 participants), a total of 285 124 participants from 46 randomised trials met the eligibility criteria; 116 145 (40·7%) were women, 168 979 (59·3%) were men, 59 185 (20·7%) had CKD at baseline, and 86 067 (30·2%) had type 2 diabetes. During a median follow-up of 4·4 years (IQR 3·2-5·1), a 5 mm Hg reduction in systolic blood pressure reduced the risk of major cardiovascular disease in individuals with CKD (hazard ratio [HR] 0·91 [95% CI 0·87-0·94]) and without CKD (0·90 [0·88-0·93]; p INTERPRETATION: In the context of cardiovascular risk reduction, the relative benefit of blood-pressure lowering in patients with CKD is similar to that in individuals without CKD, with consistent efficacy across all CKD stages, blood-pressure thresholds, and proteinuria status. However, notably, this relative benefit is attenuated in patients with CKD and concomitant diabetes, underscoring the requirement for adapted therapeutic strategies in this high-risk subgroup. Moreover, the class-specific effects of principal antihypertensives in CKD mirror those observed in the broader population, independent of CKD stage or proteinuria status. FUNDING: British Heart Foundation.
3. Physiological super-resolution in situ recording reveals kinetic changes of sympathetic norepinephrine release in heart failure.
A super-resolution Slice ElectroChemistry method enabled in situ mapping of sympathetic NE dynamics (1 μm × 1 ms × 1 nM). In pressure-overload heart failure, NE release was increased, reuptake and vesicle recycling were impaired, the releasable vesicle pool expanded, and Cav2.2 upregulation emerged as a key driver of facilitated NE release.
Impact: This work solves a technical bottleneck by enabling physiological super-resolution catecholamine mapping and reveals Cav2.2-mediated facilitation of NE release as a mechanistic contributor to heart failure progression.
Clinical Implications: Identifying Cav2.2 as a central node suggests testable therapeutic strategies targeting presynaptic calcium channels and NE handling; SEC provides a translational platform to evaluate human tissue responses.
Key Findings
- Developed Slice ElectroChemistry enabling 1 μm × 1 ms × 1 nM resolution of NE dynamics in cardiac slices.
- In TAC-induced heart failure, NE release increased while reuptake and vesicle recycling were impaired; releasable vesicle pool expanded.
- Cav2.2 calcium channel expression increased and mechanistically mediated facilitated NE release contributing to heart failure pathogenesis.
Methodological Strengths
- Physiological super-resolution and high sensitivity measurement of neurotransmitter dynamics
- Multi-dimensional validation in a well-established heart failure model with mechanistic linkage to Cav2.2
Limitations
- Preclinical model; translation to human in vivo physiology requires further validation
- Potential tissue preparation artifacts and regional sampling constraints inherent to slice methods
Future Directions: Test Cav2.2-modulating therapies in HF models and human tissues; extend SEC to other neuromodulators and organs to define sympathetic signatures across diseases.
Norepinephrine (NE) in the peripheral nervous system plays crucial roles in regulating peripheral organs in health and disease. However, the spatiotemporal dynamics of sympathetic NE release and its underlying mechanisms remain poorly characterized due to technical challenges. Here, we developed and validated a Slice ElectroChemistry (SEC) method to record sympathetic NE release in heart slices with combined super-resolution and high sensitivity at 1 μm × 1 ms × 1 nM as in patch-clamp recordings. By using the SEC method, we revealed the increased NE release, impaired NE reuptake, increased releasable NE-vesicle pool, and impaired vesicle recycling of sympathetic nerves in the heart of transverse aortic constriction-induced heart failure (HF) mouse model, and defined the increased expression of Cav2.2 calcium channel as a central mechanism mediating the facilitation of NE release and thus the pathogenesis of HF, clarifying a longstanding puzzle about the kinetic changes of cardiac sympathetic NE release in HF. Beyond the heart, SEC enables NE release recording in other peripheral organs and human tissues, providing a robust toolset to investigate sympathetic NE dynamics across diverse pathophysiological conditions.